Fresenius Medical Care AG
FME: XETR (DEU)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
€54.00 | Rkcmwp | Sth |
Fresenius Medical Care Earnings: Strong End to 2023, but Light 2024 Guidance Keeps Our FVE Intact
Narrow-moat Fresenius Medical Care turned in solid fourth-quarter results and exceeded our profit expectations for the full year, but 2024 guidance was a bit lighter than we were anticipating. Overall, though, we do not anticipate changing our fair value estimate, which remains well above recent trades.